Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
U.S. patent builds upon prior EU patent protection enabling launch of Therasure Transplant Monitor LDT and FDA kits in both the U.S. and Europe Oncocyte’s recently acquired Therasure Transplant...
-
IRVINE, Calif., Oct. 26, 2021 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics and monitoring company with the mission to improve patient outcomes by providing clear...
-
IRVINE, Calif., Oct. 07, 2021 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics and monitoring company with the mission to improve patient outcomes by providing clear...
-
IRVINE, Calif., Sept. 30, 2021 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics and monitoring company with the mission to improve patient outcomes by providing clear...
-
Randomized clinical trial data from NeoTRIPaPDL1 study establishes DetermaIO as a predictive biomarker of immunotherapy response Trial Investigators found DetermaIO outperformed 80 other immune...
-
Part 1: Transplant Rejection Testing – Wednesday, September 22nd @ 1pmET Part 2: DetermaIO™ in Triple-Negative Breast Cancer – Tuesday, September 28th @ 1pmET IRVINE, Calif., Sept. 20, 2021 (GLOBE...
-
CHICAGO, Sept. 16, 2021 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics and monitoring company with the mission to improve patient outcomes by providing clear...
-
IRVINE, Calif., Sept. 13, 2021 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics and monitoring company with the mission to improve patient outcomes by providing clear...
-
IRVINE, Calif., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics and monitoring company with the mission to improve patient outcomes by providing clear...
-
Predictive Assay for Decision Making in Adjuvant Therapy (PADMA) Registry to enroll more than 1,000 patients at 25 major hospitals treating lung cancer in the United States beginning Q4 2021 ...